Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc.ARQT · Entity 4236 | See Remarks | February 27, 2026 | March 04, 2026 |
| Oruka Therapeutics, Inc.ORKA · Entity 3781 | Chief Commercial Officer | August 24, 2026 | August 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcutis Biotherapeutics, Inc.
Report date February 27, 2026 · Filed March 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 175,178 |
Ending reported balance
After 2026-03-02 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-02-27 · Grant · Acquired 30,000 · Balance 178,865 F1: Constitute Restricted Stock Units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting, in which 25% of the RSUs vest annually on March 1, (the "Vesting Commencement Date"), of each year beginning March 1, 2027, subject to the Reporting Person's continued service to the Issuer. Row 2 · 2026-03-02 · Sale · Disposed 3,584 · Balance 175,281 F2: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. F3: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.69 to $25.67, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Row 3 · 2026-03-02 · Sale · Disposed 103 · Balance 175,178 F2: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. F4: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.70 to $26.10, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.97 · Expires 2036-02-27 | Direct | 77,000 |
Reported balance
After 2026-02-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-02-27 · Grant · Acquired 77,000 · Balance 77,000 F5: 1/48th of the shares subject to the option vest on each monthly anniversary measured from March 1, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Constitute Restricted Stock Units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting, in which 25% of the RSUs vest annually on March 1, (the "Vesting Commencement Date"), of each year beginning March 1, 2027, subject to the Reporting Person's continued service to the Issuer.
F2: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs.
F3: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.69 to $25.67, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F4: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.70 to $26.10, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F5: 1/48th of the shares subject to the option vest on each monthly anniversary measured from March 1, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.
Oruka Therapeutics, Inc.
Report date August 24, 2026 · Filed August 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 100,000 |
Reported balance
After 2026-08-24 transaction · row 1
1 source rowRow 1 · 2026-08-24 · Grant · Acquired 100,000 · Balance 100,000 F1: The grant vests as to 1/4 of the shares on September 14, 2027, with the balance vesting in 12 equal quarterly installments thereafter. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $102.42 · Expires 2036-08-23 | Direct | 20,000 |
Reported balance
After 2026-08-24 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-24 · Grant · Acquired 20,000 · Balance 20,000 F2: The option vests as to 1/4 of the underlying shares on August 24, 2027, and vests as to 1/48 of the underlying shares monthly thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The grant vests as to 1/4 of the shares on September 14, 2027, with the balance vesting in 12 equal quarterly installments thereafter.
F2: The option vests as to 1/4 of the underlying shares on August 24, 2027, and vests as to 1/48 of the underlying shares monthly thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 24, 2026 Filed Aug 25, 2026 20:25 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | GrantEmployee Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $102.42 | $0.00 |
DisclosureSEC source: 0000907654-26-000084 · form4.xml · derivative · entry 2 Edwards Larry Todd · CIK 0001994805 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2036-08-23 F2 · derivative.exercise_date: The option vests as to 1/4 of the underlying shares on August 24, 2027, and vests as to 1/48 of the underlying shares monthly thereafter. Read SEC document |
| August 24, 2026 Filed Aug 25, 2026 20:25 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000907654-26-000084 · form4.xml · nonDerivative · entry 1 Edwards Larry Todd · CIK 0001994805 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 F1 · shares: The grant vests as to 1/4 of the shares on September 14, 2027, with the balance vesting in 12 equal quarterly installments thereafter. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 01:43 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 103 | $25.91 | $2,669.23 |
DisclosureSEC source: 0001628280-26-014328 · wk-form4_1772588580.xml · nonDerivative · entry 3 Edwards Larry Todd · CIK 0001994805 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 175,178 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. F4 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.70 to $26.10, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 01:43 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 3,584 | $25.16 | $90,177.02 |
DisclosureSEC source: 0001628280-26-014328 · wk-form4_1772588580.xml · nonDerivative · entry 2 Edwards Larry Todd · CIK 0001994805 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 175,281 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. F3 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.69 to $25.67, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 01:43 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (right to buy) · Derivative | 77,000 | $0.00 Strike: $26.97 | $0.00 |
DisclosureSEC source: 0001628280-26-014328 · wk-form4_1772588580.xml · derivative · entry 4 Edwards Larry Todd · CIK 0001994805 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 77,000 Underlying: Common Stock · 77,000 shares Expires 2036-02-27 F5 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from March 1, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 01:43 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-014328 · wk-form4_1772588580.xml · nonDerivative · entry 1 Edwards Larry Todd · CIK 0001994805 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 178,865 F1 · kind: Constitute Restricted Stock Units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting, in which 25% of the RSUs vest annually on March 1, (the "Vesting Commencement Date"), of each year beginning March 1, 2027, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| February 02, 2026 Filed Feb 5, 2026 00:21 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 2,052 | $25.50 | $52,322.72 |
DisclosureSEC source: 0001628280-26-005566 · wk-form4_1770250865.xml · nonDerivative · entry 1 Edwards Larry Todd · CIK 0001994805 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 148,865 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligation in connection with the vesting of Restricted Stock Units ("RSUs"), granted on January 12, 2024, in which 25% of the RSUs vest annually on February 1, (the "Vesting Commencement Date"), of each year beginning on February 1, 2025, subject to the Reporting Person's continued service to the Issuer. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.745 to $25.68, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 724 shares purchased under the Issuer's Employee Stock Purchase Plan on November 30, 2025. Read SEC document |
| November 06, 2025 Filed Nov 10, 2025 22:42 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 29,131 | $25.16 | $732,927.22 |
DisclosureSEC source: 0001994805-25-000008 · wk-form4_1762814533.xml · nonDerivative · entry 1 Edwards Larry Todd · CIK 0001994805 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,193 F1 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.2600, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| October 02, 2025 Filed Oct 6, 2025 19:15 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 297 | $20.78 | $6,171.69 |
DisclosureSEC source: 0001994805-25-000005 · wk-form4_1759778121.xml · nonDerivative · entry 2 Edwards Larry Todd · CIK 0001994805 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 179,324 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units granted on February 22, 2024. F3 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $20.5593 to $20.995, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F4 · balance_after: Includes 724 shares purchased under the Issuer's Employee Stock Purchase Plan on May 31, 2025. Read SEC document |
| October 02, 2025 Filed Oct 6, 2025 19:15 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 4,207 | $19.99 | $84,091.62 |
DisclosureSEC source: 0001994805-25-000005 · wk-form4_1759778121.xml · nonDerivative · entry 1 Edwards Larry Todd · CIK 0001994805 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 178,897 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units granted on February 22, 2024. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $19.545 to $20.502, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| May 19, 2025 Filed May 20, 2025 20:37 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 7,451 | $14.07 | $104,849.73 |
DisclosureSEC source: 0002065881-25-000009 · wk-form4_1747773410.xml · nonDerivative · entry 1 Edwards Larry Todd · CIK 0001994805 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 183,104 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") granted on February 22, 2024. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $13.6763 to $14.49, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| February 28, 2025 Filed Mar 5, 2025 00:43 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (right to buy) · Derivative | 43,000 | $0.00 Strike: $13.69 | $0.00 |
DisclosureSEC source: 0001787306-25-000039 · wk-form4_1741135393.xml · derivative · entry 4 Edwards Larry Todd · CIK 0001994805 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,000 Underlying: Common Stock · 43,000 shares Expires 2035-02-28 F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from March 1, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| February 28, 2025 Filed Mar 5, 2025 00:43 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (right to buy) · Derivative | 99,000 | $0.00 Strike: $13.69 | $0.00 |
DisclosureSEC source: 0001787306-25-000039 · wk-form4_1741135393.xml · derivative · entry 3 Edwards Larry Todd · CIK 0001994805 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,000 Underlying: Common Stock · 99,000 shares Expires 2035-02-28 F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from March 1, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| February 28, 2025 Filed Mar 5, 2025 00:43 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 17,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001787306-25-000039 · wk-form4_1741135393.xml · nonDerivative · entry 2 Edwards Larry Todd · CIK 0001994805 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,555 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting, in which 25% of the RSUs vest annually on March 1, (the "Vesting Commencement Date"), of each year beginning March 1, 2026, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| February 28, 2025 Filed Mar 5, 2025 00:43 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 38,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001787306-25-000039 · wk-form4_1741135393.xml · nonDerivative · entry 1 Edwards Larry Todd · CIK 0001994805 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,555 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting, in which 25% of the RSUs vest annually on March 1, (the "Vesting Commencement Date"), of each year beginning March 1, 2026, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 01:00 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 2,173 | $12.70 | $27,597.10 |
DisclosureSEC source: 0001787306-25-000013 · wk-form4_1738717233.xml · nonDerivative · entry 1 Edwards Larry Todd · CIK 0001994805 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 135,555 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs"), granted on January 12, 2024, in which 25% of the RSUs vest annually on February 1, (the "Vesting Commencement Date"), of each year beginning on February 1, 2025, subject to the Reporting Person's continued service to the Issuer. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $12.545 to $13.0096, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Reflects the adjusted total which includes the acquisition of 1,093 shares under the Company's Employee Stock Purchase Plan on November 30, 2024, respectively, which transactions were exempt from Section 16(a) and (b) and were erroneously reported as non-exempt purchases in the Reporting Person's Form 4 filed on December 3, 2024. Read SEC document |
| November 30, 2024 Filed Dec 3, 2024 21:17 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | PurchaseCommon Stock | 1,093 | $7.11 | $7,766.86 |
DisclosureSEC source: 0001787306-24-000169 · wk-form4_1733260622.xml · nonDerivative · entry 1 Edwards Larry Todd · CIK 0001994805 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,728 F1 · shares: Pursuant to the purchase transaction of the Company's Employee Stock Purchase Plan. Read SEC document |
| October 02, 2024 Filed Oct 3, 2024 20:55 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 3,725 | $10.01 | $37,295.45 |
DisclosureSEC source: 0001787306-24-000136 · wk-form4_1727988928.xml · nonDerivative · entry 1 Edwards Larry Todd · CIK 0001994805 · SVP Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 136,635 F1 · kind: The sale was made pursuant to the Issuer's mandatory sell-to-cover requirements implemented to satisfy the tax withholding obligations associated with the vesting of the Reporting Person's Restricted Stock Units ("RSUs"). F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $9.51 to $10.31, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| May 17, 2024 Filed May 20, 2024 21:12 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 7,640 | $8.98 | $68,581.99 |
DisclosureSEC source: 0001787306-24-000081 · wk-form4_1716239548.xml · nonDerivative · entry 2 Edwards Larry Todd · CIK 0001994805 · SVP Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,360 F2 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the RSUs, the shares were sold upon the vesting of the RSUs solely to cover applicable tax withholding. F3 · price: The transaction was executed in multiple trades in prices ranging from $8.76 to $9.115, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| May 16, 2024 Filed May 20, 2024 21:12 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001787306-24-000081 · wk-form4_1716239548.xml · nonDerivative · entry 1 Edwards Larry Todd · CIK 0001994805 · SVP Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,000 F1 · shares: Represents Restricted Stock Units ("RSUs"), initially granted on February 22, 2024, in which the shares were subject to a performance-based vesting condition, which was deemed satisfied on May 16, 2024 (the "Vesting Commencement Date"). Therefore, 50% of the shares vested on May 16, 2024 and the remaining 50% of the shares vest on May 16, 2025, subject to the Reporting Person's continued service with the Company through the applicable vesting date. Read SEC document |
| January 12, 2024 Filed Jan 17, 2024 21:34 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (right to buy) · Derivative | 176,000 | $0.00 Strike: $3.64 | $0.00 |
DisclosureSEC source: 0001787306-24-000010 · wk-form4_1705527248.xml · derivative · entry 2 Edwards Larry Todd · CIK 0001994805 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,000 Underlying: Common Stock · 176,000 shares Expires 2034-01-12 F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| January 12, 2024 Filed Jan 17, 2024 21:34 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 28,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001787306-24-000010 · wk-form4_1705527248.xml · nonDerivative · entry 1 Edwards Larry Todd · CIK 0001994805 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,000 F1 · shares: Constitute Restricted Stock Units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting. 25% of the RSUs vest annually on February 1, (the "Vesting Commencement Date"), of each year, beginning on February 1, 2025, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| September 27, 2023 Filed Oct 4, 2023 01:45 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (right to buy) · Derivative | 240,000 | $0.00 Strike: $5.58 | $0.00 |
DisclosureSEC source: 0001787306-23-000113 · wk-form4_1696383903.xml · derivative · entry 2 Edwards Larry Todd · CIK 0001994805 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,000 Underlying: Common Stock · 240,000 shares Expires 2033-09-27 F2 · derivative.exercise_date: The option will vest and become exercisable as to 25% of the shares subject to the option on October 1, 2024, and the remaining options will vest at 2.0833% subject to the options on each monthly anniversary thereafter, subject to Reporting Person's continued service through the applicable vesting date. Read SEC document |
| September 27, 2023 Filed Oct 4, 2023 01:45 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001787306-23-000113 · wk-form4_1696383903.xml · nonDerivative · entry 1 Edwards Larry Todd · CIK 0001994805 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 F1 · shares: The Restricted Stock Units ("RSUs") will vest as to 25% of the RSUs on each annual anniversary of October 1, 2023, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.